Modelling Health State Utilities as a Transformation of Time to Death in Patients with Non-Small Cell Lung Cancer

Anthony J. Hatswell (), Mohammad A. Chaudhary, Giles Monnickendam, Alejandro Moreno-Koehler, Katie Frampton, James W. Shaw, John R. Penrod and Rachael Lawrance
Additional contact information
Anthony J. Hatswell: Delta Hat
Mohammad A. Chaudhary: Bristol Myers Squibb
Giles Monnickendam: Ceelos Consulting
Alejandro Moreno-Koehler: Adelphi Values LLP
Katie Frampton: Adelphi Values Ltd
James W. Shaw: Bristol Myers Squibb
John R. Penrod: Bristol Myers Squibb
Rachael Lawrance: Adelphi Values Ltd

PharmacoEconomics, 2024, vol. 42, issue 1, No 8, 109-116

Abstract: Abstract Background When utilities are analyzed by time to death (TTD), this has historically been implemented by ‘grouping’ observations as discrete time periods to create health state utilities. We extended the approach to use continuous functions, avoiding assumptions around groupings. The resulting models were used to test the concept with data from different regions and different country tariffs. Methods Five-year follow-up in advanced non-small cell lung cancer (NSCLC) was used to fit six continuous TTD models using generalized estimating equations, which were compared with progression-based utilities and previously published TTD groupings. Sensitivity analyses were performed using only patients with a confirmed death, the last year of life only, and artificially censoring data at 24 months. The statistically best-fitting model was then applied to data subsets by region and different EQ-5D-3L country tariffs. Results Continuous (natural) $$\mathrm{Log}(TTD)$$ Log ( T T D ) and $$1/\sqrt{TTD}$$ 1 / TTD models outperformed other continuous models, grouped TTD, and progression-based models in statistical fit (mean absolute error and Quasi Information Criterion). This held through sensitivity and scenario analyses. The pattern of reduced utility as a patient approaches death was consistent across regions and EQ-5D tariffs using the preferred $$\mathrm{Log}(TTD)$$ Log ( T T D ) model. Conclusions The use of continuous models provides a statistically better fit than TTD groupings, without the need for strong assumptions about the health states experienced by patients. Where a TTD approach is merited for use in modelling, continuous functions should be considered, with the scope for further improvements in statistical fit by both widening the number of candidate models tested and the therapeutic areas investigated.

Date: 2024
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40273-023-01314-2 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:42:y:2024:i:1:d:10.1007_s40273-023-01314-2

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.1007/s40273-023-01314-2

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().